<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009772</url>
  </required_header>
  <id_info>
    <org_study_id>Antibiotic CS</org_study_id>
    <nct_id>NCT04009772</nct_id>
  </id_info>
  <brief_title>Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section</brief_title>
  <official_title>Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yasser Esmat Mohammed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare between cefepime versus routine antibiotics as a prophylactic antibiotic during
      emergency cesarean section in a tertiary center of obstetric care
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double blinded study which compare between single dose cefepime versus
      cefuroxime plus metronidazole during emergency intrapartum cesarean section.

      Outcomes will include fever, wound infection, and urinary tract infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of surgical site wound infection</measure>
    <time_frame>one week</time_frame>
    <description>Examining the wound after one week of the surgery to detect any infection</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Emergency Cesarean Section</condition>
  <condition>Infection Wound</condition>
  <arm_group>
    <arm_group_label>&quot;Cefepime&quot; , &quot;Maxipime®&quot; 1 gm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive &quot;Cefepime&quot; ,&quot;Maxipime®&quot; 1 gm IV during cesarean section just before skin incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Cefuroxime&quot;, &quot;Zinnat®&quot; 1gm plus &quot;metronidazole&quot;Flagyl®&quot; 500</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive &quot;Cefuroxime&quot;, &quot;Zinnat®&quot; 1gm ,and &quot;metronidazole&quot;Flagyl®&quot; 500 IV; just before skin incision for emergency cesarean section</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefepime</intervention_name>
    <description>Antibiotic prophylaxis</description>
    <arm_group_label>&quot;Cefepime&quot; , &quot;Maxipime®&quot; 1 gm</arm_group_label>
    <other_name>Maxipime</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime plus Metronidazole</intervention_name>
    <description>Antibiotic prophylaxis</description>
    <arm_group_label>&quot;Cefuroxime&quot;, &quot;Zinnat®&quot; 1gm plus &quot;metronidazole&quot;Flagyl®&quot; 500</arm_group_label>
    <other_name>Zinnat plus Flagyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  intrapartum caesarean section

        Exclusion Criteria:

          -  evidence of infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abdalmageed Abdalmageed</last_name>
    <phone>+201007972027</phone>
    <email>drosamast@yahoo.com.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Osama Abdalmageed</last_name>
    <phone>01007972027</phone>
    <email>drosamast1981@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdalmageed</last_name>
      <phone>1007972027</phone>
      <email>drosamast@yahoo.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Osama Saber Thabet Abdalmageed</investigator_full_name>
    <investigator_title>Consultant of Obstetrics and gynecology</investigator_title>
  </responsible_party>
  <keyword>Cefepime, Cefuroxime, Metronidazole, Cesarean, Intrapartum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

